Navigation Links
New Drug to Prevent Bone Loss Caused by Breast Cancer Treatment
Date:12/15/2007

SAN ANTONIO, Dec. 15 /PRNewswire/ -- Denosumab is a new drug being studied to prevent fractures in breast cancer patients receiving hormonal therapy. Results of a phase 3 clinical trial using denosumab were presented Friday evening at the San Antonio Breast Cancer Symposium by Georgiana Ellis, MD, from the Seattle Cancer Care Alliance.

Denosumab is a highly specific antibody that interrupts the development of osteoclasts -- specialized cells that break down bone. Because it is highly specific, the chance of systemic effects in other parts of the body is low, so patients do not need routine laboratory monitoring.

A group of drugs called aromatase inhibitors is used to prevent the recurrence of breast cancer in postmenopausal women. These drugs are very effective, but commonly associated with loss of bone density and an increased risk of fractures.

To test the effectiveness of denosumab in preventing bone loss caused by aromatase inhibitors, a clinical trial recruited 252 patients who had been treated for early stage breast cancer and for whom treatment with anastrozole, an aromatase inhibitor, was planned. Half of the patients were given denosumab, while the other half was not. All patients were instructed to take daily doses of calcium and vitamin D.

The study lasted for 2 years, with patients receiving an injection of denosumab every 6 months. All the women from both groups had their lumbar spine bone density measured at the end of the first and second years. By the end of the first year, the bone density of the women receiving denosumab had increased by nearly 5%, while the women who did not receive denosumab had bone density decreases of almost 1%. By the end of the second year, the difference was even greater: in the women receiving denosumab, bone density had increased by almost 6%, while the bone density of the women who did not receive denosumab decreased by nearly 2%. Similar effects on bone density were seen at the hip and the wrist. Side effects of denosumab were similar to those reported in the control group.

Denosumab appears to be a safe and effective treatment for preventing bone loss in women taking aromatase inhibitors, offering an alternative to existing therapies, such as oral or intravenous bisphosphonates.


'/>"/>
SOURCE San Antonio Breast Cancer Symposium
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Flash Technology Prevents Pain From Carpal Tunnel Syndrome
2. International Atomic Energy Agency and National Foundation for Cancer Research Launch Major Initiative to Improve Cancer Prevention and Treatments in Developing Countries
3. New White Paper Details Six Steps to Investigate and Prevent Laboratory Accidents
4. Protherics UK Ltd. Chooses TrackWise for Corrective Action and Preventive Action (CAPA) Management
5. Leading Edge Research Underway in Fall Prevention for Seniors
6. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
7. Individual differences caused by shuffled chunks of DNA in the human genome
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
10. Imaging Diagnostic Systems New Laser Breast Imaging Scanner Introduced in Malaysia
11. NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... MD (PRWEB) , ... April 20, 2017 , ... ... the formation of a unique intellectual property (IP) sharing and commercialization model. , ... most promising inventions. A main component of this effort is bringing the IP ...
(Date:4/20/2017)... YORK , April 20, 2017 ... that focuses on novel drug development and clinical research aimed ... are: Biostage Inc. (NASDAQ: BSTG), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), ... ZIOP ). You can access our complimentary research ... ...
(Date:4/19/2017)... , ... April 18, 2017 , ... Alisa Wright, founder ... Alumni Awards from the Purdue College of Pharmacy in Lafayette, Indiana. , The ... Program for achievements in their careers and other scientific endeavors. , Wright began ...
(Date:4/19/2017)... (PRWEB) , ... April 19, 2017 , ... ... $1.5M Series A-1 financing round. This event adds to several other early achievements ... its’ Executive and Scientific Teams. , ThermaGenix will use proceeds from ...
Breaking Biology Technology:
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
Breaking Biology News(10 mins):